Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
apothederm, Biopharma, broaden, Caregen, category, Chase, communicated, compound, corruption, coupled, CRODA, cumulative, currency, denominated, disruption, dollar, DSM, ensure, Europe, factor, feedback, GlobalData, guarantor, highest, intelligence, irrevocable, JP, JPMorgan, left, lender, Lipotec, LOC, Lonza, Lytix, mark, maximum, Morgan, niche, nonfinancial, officially, overcrowding, palmitoyl, photodynamic, progressive, published, ranking, recoverable, relaunched, retire, salary, similarly, soothing, specialist, standby, stipulate, stretch, tissue, top, uniform, unused
Removed:
accelerated, Agennix, aim, allocate, allocated, area, attestation, auction, breakdown, BV, capitalization, collagen, credited, deliverable, derivative, detailed, Dr, elastin, element, embedded, exceeding, excluding, extend, extinguished, extinguishment, Falla, governed, hold, impart, initiation, instrument, invested, joint, marketable, Migenix, modified, objective, obligated, par, Pentapharm, permanent, Pharma, platform, PLC, prepayment, proliferation, promise, prospectively, recent, recording, redeem, replaced, requirement, resiliency, Rodan, SAS, Sederma, Senetek, separated, separately, settlement, stimulation, thereunder, Timothy, undelivered, unit, unrealized
Filing tables
Filing exhibits
HXBM similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Helix BioMedix, Inc.
We consent to the incorporation by reference in the registration statements (Nos. 333-136192 and 333-176273) on Form S-8 of Helix BioMedix Inc. of our report dated March 27, 2012, with respect to the balance sheets of Helix BioMedix, Inc. as of December 31, 2011 and 2010, and the related statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2011, which report appears in the December 31, 2011 annual report on Form 10-K of Helix BioMedix, Inc.
/s/ KPMG LLP
Seattle, Washington
March 27, 2012